Quick Answer
KIORA PHARMACEUTICALS INC reported Cash and Equivalents of $8.70 million for fiscal year 2025.
KIORA PHARMACEUTICALS INC Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $8.70M | +129.3% |
| 2024 | $3.79M | +54.5% |
| 2023 | $2.45M | -58.8% |
| 2022 | $5.96M | -24.1% |
| 2021 | $7.85M | +562.5% |
| 2020 | $1.19M | -68.6% |
| 2019 | $3.78M | -52.8% |
| 2018 | $8.00M | +2.5% |
| 2017 | $7.81M | +114.7% |
| 2016 | $3.64M | -56.7% |
| 2015 | $8.39M | +4926.4% |
| 2014 | $167.0K | -66.7% |
| 2013 | $501.2K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $5.51M | -2.3% | +435.7% |
| June 30, 2025 | $1.03M | -84.4% | -72.7% |
| March 31, 2025 | $3.77M | -87.9% | -0.6% |
| December 31, 2024 | $3.79M | +54.5% | -32.7% |
| September 30, 2024 | $5.64M | +4.4% | -14.3% |
| June 30, 2024 | $6.58M | -17.3% | -79.0% |
| March 31, 2024 | $31.28M | +812.9% | +1174.1% |
| December 31, 2023 | $2.45M | -58.8% | -54.5% |
- KIORA PHARMACEUTICALS INC showed an increase of +129.3% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2013–2025 period, KIORA PHARMACEUTICALS INC’s cash and equivalents has grown by 1635.2% (from $501.2 thousand to $8.70 million).
- The most recent figure is from KIORA PHARMACEUTICALS INC’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: